GeoVax Labs reported a second-quarter 2026 net loss of $4,426,578 ($0.97 per share) and cash and cash equivalents of approximately $3.1 million as of June 30, 2026. The company said revenue from its prior BARDA contract ceased in 2026 following termination for convenience, and R&D and G&A expenses declined versus the prior-year periods. GeoVax Labs highlighted operational progress toward initiating a pivotal GEO‑MVA immunobridging study under an expedited EMA pathway and continued advancement of its Gedeptin immuno‑oncology program.

Financial Highlights

  • Net loss (three months ended June 30, 2026): $4,426,578 (loss per share $0.97).
  • Net loss (six months ended June 30, 2026): $9,688,499 (loss per share $2.94).
  • Revenue: $0 for the three- and six-month periods ended June 30, 2026 (compared with $852,282 and $2,489,145 in 2025 related to a BARDA contract).
  • Research and development expense (Q2 2026): $3,110,508; six months: $7,013,971.
  • General and administrative expense (Q2 2026): $1,331,564; six months: $2,700,982.
  • Cash and cash equivalents: approximately $3.1 million at June 30, 2026 ( $3,143,000 reported).

Business Highlights

  • GEO‑MVA pivotal immunobridging study: Continued clinical study readiness, manufacturing preparedness and start‑up activities in advance of a planned fourth‑quarter 2026 initiation under an expedited regulatory pathway aligned with EMA Scientific Advice.
  • Manufacturing: Utilization of previously manufactured and released cGMP clinical trial material to support study readiness and advancement of the AGE1 continuous cell‑line platform to support future commercial‑scale MVA vaccine manufacturing.
  • Stakeholder engagement: Ongoing engagement with government, public health and biodefense stakeholders regarding long‑term orthopoxvirus preparedness and vaccine supply requirements.
  • Gedeptin program: Continued advancement of Gedeptin (GDEPT) toward combination immunotherapy strategies to enhance PD‑1 checkpoint inhibitor activity, supported by an exclusive license from Emory University for combinations with immune checkpoint inhibitors.
  • Strategic focus: Company reprioritized development portfolio in May 2026 to concentrate resources on GEO‑MVA and Gedeptin, discontinuing active development of the GEO‑CM04S1 COVID‑19 candidate (decision not related to safety or efficacy).

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.